Breast Cancer Canada, AstraZeneca Canada and Illumina Join Forces to Launch Grants to Support Breast Cancer Screening and Detection
Friday, June 16, 2023
Today Breast Cancer Canada , a national charity dedicated to saving lives through breast cancer research, announces a new research grant in collaboration with AstraZeneca Canada , a global biopharmaceutical company, and Illumina , a world leader in DNA sequencing and multi-sample technologies. Breast Cancer Canada also announced the recipients of its annual Precision Oncology Research Grants.
Breast Cancer Canada and AstraZeneca Canada will jointly award $200,000 to Canadian research teams using precision diagnostics and AI to advance breast cancer screening and detection. Illumina will help fuel the collaboration by providing donations in the form of sequencing consumables. Eligible research teams must focus on the discovery and development of quality testing and analytical techniques for the general population in breast cancer screening, thereby accelerating the new era of personalized medicine. Breast Cancer Canada and AstraZeneca Canada will be looking for researchers who use new precision or personalized technology, including blood tests or imaging that identify breast cancer during screening, and machine learning that helps clinicians more accurately detect breast cancer. The submission period will begin on July 3, 2023.
“By investing in Canadian breast cancer screening research, Breast Cancer Canada and AstraZeneca Canada are advancing technological innovation to diagnose disease earlier, faster and before symptoms. We want to find research teams to revolutionize breast cancer detection,” says Kimberly Carson, CEO, Breast Cancer Canada. “The advances we seek will focus on better, less invasive and more accessible testing techniques for Canadian women. »
“At AstraZeneca, we are committed to fully expressing what science can do to redefine cancer care and set new standards for patient outcomes. This includes helping to identify cancers earlier so patients have the best chance of a cure,” says Brian Seguin, AstraZeneca Canada, Director — Breast Cancer. "We are proud to join forces with Breast Cancer Canada to support research that will not only improve health outcomes for women with breast cancer, but also build health care capacity in areas of screening and early diagnosis. »
“Illumina is pleased to join this effort and support research to leverage genomics and AI technologies to drive innovation in breast cancer screening and detection capabilities,” Nicki said. Berry, Americas Region Manager, Illumina. “We are delighted to see the fruit of these efforts to improve personalized medicine for patients.
The partnership between AstraZeneca Canada and Illumina follows Breast Cancer Canada's second annual precision oncology research grant. Researchers from across Canada were invited to submit projects last December for funding in 2023. Selected projects relate to one of the four divisions of precision oncology research identified by the scientific advisory committee: basic science, screening and detection, personalized treatment and patient-reported outcomes. All projects must also include an artificial intelligence (AI) component and a patient advocate actively involved in research.
About Breast Cancer Canada
Breast Cancer Canada is a national charitable organization dedicated to saving lives through breast cancer research. With a focus on precision oncology (personalized care), it is the only national breast cancer organization in Canada with a clear mandate to raise funds for research. The organization receives no government funding, which means that all research is funded through the generosity of donors. For more information, visit breastcancerprogress.ca .
About AstraZeneca Canada
AstraZeneca is a global biopharmaceutical company focused on the innovation, discovery, development and delivery of life-changing medicines, with a core science focus in the areas of oncology; cardiovascular, renal and metabolic diseases; rare diseases; respiratory and immunological diseases; and vaccines and immune therapies. AstraZeneca operates in more than 100 countries and its innovative medicines are used by millions of patients worldwide.
About Illumina
Illumina improves human health by unlocking the power of the genome. In 2023, we celebrate 25 years of innovation, which has allowed us to become a world leader in DNA sequencing and multi-sample technologies, serving customers in the research, clinical and applied. Our products are used for applications in life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit illumina.com .
The text of the press release resulting from a translation should in no way be considered official. The only authentic version of the press release is that of the press release in its original language. The translation will always have to be compared with the source text, which will set a precedent.
contacts
Media
Lindsay Silverberg
Senior Account Manager
lindsay@talkshopmedia.com
